LumiThera Announced the Result of US LIGHTSITE III Trial of Non-neovascular Age-Related Macular Degeneration (AMD) Subjects Treated with Photobiomodulation (PBM) using the Valeda® Light Delivery System
On June 22, 2022, LumiThera Inc., a commercial-stage medical device company offering photobiomodulation (PBM) treatment for ocular damage and disease, released the results of its US LIGHTSITE III multi-center clinical trial of non-neovascular (dry) age-related macular degeneration (AMD) patients treated with photobiomodulation (PBM) using the valeda® light delivery system.
The company conducted the trial at ten leading US retinal centers. LIGHTSITE III is a prosp...
